Free Trial

This company has been marked as potentially delisted and may not be actively trading.

resTORbio (TORC) Competitors

resTORbio logo

TORC vs. WHWK, SPRB, LITS, AADI, ELYM, ATNM, NBRV, EGRX, PYRGF, and LNAI

Should you be buying resTORbio stock or one of its competitors? The main competitors of resTORbio include Whitehawk Therapeutics (WHWK), Spruce Biosciences (SPRB), Lite Strategy (LITS), Aadi Bioscience (AADI), Eliem Therapeutics (ELYM), Actinium Pharmaceuticals (ATNM), Nabriva Therapeutics (NBRV), Eagle Pharmaceuticals (EGRX), PyroGenesis Canada (PYRGF), and Lunai Bioworks (LNAI).

resTORbio vs. Its Competitors

resTORbio (NASDAQ:TORC) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

In the previous week, Whitehawk Therapeutics had 5 more articles in the media than resTORbio. MarketBeat recorded 5 mentions for Whitehawk Therapeutics and 0 mentions for resTORbio. Whitehawk Therapeutics' average media sentiment score of 1.10 beat resTORbio's score of 0.00 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
resTORbio Neutral
Whitehawk Therapeutics Positive

resTORbio has a beta of 2.43, meaning that its stock price is 143% more volatile than the S&P 500. Comparatively, Whitehawk Therapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500.

46.2% of resTORbio shares are held by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are held by institutional investors. 11.8% of resTORbio shares are held by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Whitehawk Therapeutics has higher revenue and earnings than resTORbio. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than resTORbio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
resTORbioN/AN/A-$82.74M-$2.41-0.40
Whitehawk Therapeutics$25.98M3.66-$63.69M-$0.06-33.67

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
resTORbio
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Whitehawk Therapeutics
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Whitehawk Therapeutics has a net margin of 99.42% compared to resTORbio's net margin of 0.00%. Whitehawk Therapeutics' return on equity of -75.99% beat resTORbio's return on equity.

Company Net Margins Return on Equity Return on Assets
resTORbioN/A -78.12% -71.63%
Whitehawk Therapeutics 99.42%-75.99%-68.57%

Summary

Whitehawk Therapeutics beats resTORbio on 11 of the 13 factors compared between the two stocks.

Get resTORbio News Delivered to You Automatically

Sign up to receive the latest news and ratings for TORC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TORC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TORC vs. The Competition

MetricresTORbioPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$35.26M$791.27M$6.10B$10.63B
Dividend YieldN/A4.84%5.67%4.71%
P/E Ratio-0.531.3085.2726.57
Price / SalesN/A29.35612.78132.63
Price / CashN/A17.6438.5062.09
Price / Book0.437.3112.726.53
Net Income-$82.74M-$7.96M$3.30B$275.96M

resTORbio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TORC
resTORbio
N/A$0.97
+5.8%
N/A-35.6%$35.26MN/A-0.53N/A
WHWK
Whitehawk Therapeutics
0.9896 of 5 stars
$2.13
-4.1%
N/AN/A$100.39M$25.98M-35.5021News Coverage
Positive News
Analyst Upgrade
Gap Down
SPRB
Spruce Biosciences
0.6565 of 5 stars
$160.07
-12.3%
$131.25
-18.0%
+429.6%$89.64M$4.91M-1.8620High Trading Volume
LITS
Lite Strategy
N/A$2.50
+2.0%
N/AN/A$89.13M$65.30M-0.53100News Coverage
Analyst Forecast
Gap Up
AADI
Aadi Bioscience
N/A$2.22
+3.3%
N/A+9.0%$54.83M$25.07M-0.9740
ELYM
Eliem Therapeutics
N/A$1.81
-8.6%
N/A-65.1%$53.85MN/A-3.429
ATNM
Actinium Pharmaceuticals
1.8663 of 5 stars
$1.54
-2.5%
$4.50
+192.2%
-8.6%$48.04MN/A-1.1130
NBRV
Nabriva Therapeutics
N/AN/AN/AN/A$45.46M$35.59M0.0070
EGRX
Eagle Pharmaceuticals
1.3471 of 5 stars
$3.00
flat
N/A+166.7%$38.96M$257.55M0.00100Gap Down
PYRGF
PyroGenesis Canada
N/A$0.19
+3.3%
N/A-69.2%$35.50M$9.14M-3.1690Gap Down
LNAI
Lunai Bioworks
N/A$1.24
-1.6%
N/AN/A$28.74MN/A-0.1620Analyst Forecast

Related Companies and Tools


This page (NASDAQ:TORC) was last updated on 10/11/2025 by MarketBeat.com Staff
From Our Partners